Evidence map›Paper›PMID 40836149›Full record

ArticleAnnals of surgical oncology2025

The Effect of Chronic Liver Disease on Adverse In-Hospital Outcomes After Radical Cystectomy and Ileal Conduit Urinary Diversion.

Federico Polverino, Andrea Marmiroli, Mattia Longoni, Quynh Chi Le, Fabian Falkenbach, Michele Nicolazzini, Calogero Catanzaro, Fred Saad, Jordan A Goyal, Simone Morra and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Federico PolverinoCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada. fedepolve97@gmail.com.ORCID http://orcid.org/0009-0007-6218-3761
Andrea MarmiroliCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Mattia LongoniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Quynh Chi LeCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Fabian FalkenbachCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Michele NicolazziniCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Calogero CatanzaroCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Fred SaadCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Jordan A GoyalCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Simone MorraCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Gianluigi CalifanoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Roberto La RoccaDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Claudia Collà RuvoloCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.
Alberto BrigantiVita-Salute San Raffaele University, Milan, Italy.
Felix K H ChunDepartment of Urology, Goethe University Frankfurt, University Hospital, Frankfurt am Main, Germany.
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Carlotta PalumboDivision of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy.
Riccardo SchiavinaDivision of Urology, IRCCS Azienda Ospedaliero-universitaria di Bologna, Bologna, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.
Shahrokh F ShariatDepartment of Urology, Weill Cornell Medical College, New York, NY, USA.
Nicola LongoDepartment of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.
Pierre I KarakiewiczCancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadical cystectomy (RC) is the gold standard treatment for muscle-invasive bladder cancer (BCa). Chronic liver disease (CLD) may predispose to worse in-hospital outcomes after RC and ileal conduit, but this association has not been investigated. The current study addressed this knowledge gap.

methodsDescriptive analyses, propensity score-matching (PSM), and multivariable logistic and Poisson regression models were used to address BCa patients in the National Inpatient Sample treated with RC and ileal conduit (2006-2019).

resultsOf 15,104 RC and ileal conduit patients, 241 (1.6 %) had CLD at baseline. Compared with their non-CLD counterparts, the CLD patients exhibited significantly higher rates of adverse in-hospital outcomes in 9 of 13 categories, namely, acute kidney injury (AKI, Δ+12.0 %), overall complications (Δ+11.0 %), pulmonary complications (Δ+9.0 %), blood transfusions (Δ+8.0 %), prolonged hospital stay (Δ+7.0 %), infectious complications (Δ+7.0 %), critical care therapies (Δ+4.0 %), in-hospital mortality (Δ+3.6 %), and total hospital charges (THC, Δ+18, 042 US$) (all p < 0.05). After multivariable adjustment, CLD independently predicted higher rates of adverse in-hospital outcomes in the same categories, namely, in-hospital mortality (odds ratio [OR], 2.7; 95 % confidence interval [CI], 1.3-4.9), infectious complications (OR, 2.5; 95 % CI 1.6-3.8), AKI (OR, 2.1; 95 % CI 1.6-2.9), pulmonary complications (OR, 2.0; 95 % CI 1.4-2.8), overall complications (OR, 1.9; 95 % CI 1.7-2.9), critical care therapies (OR, 1.6; 95 % CI 1.2-1.9), blood transfusions (OR, 1.4; 95 % CI 1.1-1.9), prolonged hospital stay (OR, 1.4; 95 % CI 1.1-1.8), and THC (OR, 1.2; 95 % CI 1.1-1.4) (all p < 0.05).

conclusionsAlthough CLD appears to predispose to higher rates of adverse in-hospital outcomes after RC and ileal conduit, it does not increase the rates of these outcomes in a prohibitive fashion.

Indexed as

CystectomyLiver DiseasesPostoperative ComplicationsUrinary Bladder NeoplasmsUrinary DiversionAgedChronic DiseaseFemaleFollow-Up StudiesHospital MortalityHumansLength of StayMaleMiddle AgedPrognosisPropensity Score

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.